77 / 164
337
[Aspectos diagnósticos y terapéuticos en el mesotelioma pleural maligno - Dr. Francisco Rodríguez P.]
relieving dyspnea in patients with malignant pleural
effusion. The TIME2 randomized controlled trial. JAMA.
2012;307:2383-9.
102. Lorenzo MJ, Modesto M, Pérez J, et al. Quality-of-Life
assessment in malignant pleural effusion treated with
indwelling pleural catheter: A prospective study. Palliat Med.
2014;28:326-34.
103. Ostroff RM, Mehan MR, Stewart A, et al. Early detection
of malignant pleural mesothelioma in asbestos-exposed
individuals with a noninvasive proteomics-based surveillance
tool. PLoS One. 2012;7:e46091.
104. Mundt F, Johansson HJ, Forshed J, et al. Proteome screening
of pleural effusions identifies galectin 1 as a diagnostic
biomarker and highlights several prognostic biomarkers
for malignant mesothelioma. Mol Cell Proteomics.
2014;13:701-15.
105. Gueugnon F, Leclercq S, Blanquart C, et al. Identification
of novel markers for the diagnosis of malignant pleural
mesothelioma. Am J Pathol. 2011;178:1033-42.
106. López-Campos JL, Sánchez Silva R, Gómez Izquierdo L, et
al. Overexpression of Aquaporin-1 in lung adenocarcinomas
and pleural mesotheliomas. Histol Histopathol. 2011
Apr;26(4):451-9.
107. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S.
Challenges and controversies in the diagnosis of malignant
mesothelioma: Part 2. Malignant mesothelioma subtypes,
pleural synovial sarcoma, molecular and prognostic aspects
of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin
Pathol. 2013;66:854-61.
108. Kao SC, Armstrong N, Condon B, et al. Aquaporin 1 is
an independent prognostic factor in pleural malignant
mesothelioma. Cancer. 2012;118:2952-61.
109. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds
of conserved and nonconserved human microRNAs. Nat
Genet. 2005 Jul;37(7):766-70.
110. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay
based on microRNA expression accurately identifies malignant
pleural mesothelioma. J Mol Diagn. 2010;12:771–79.
111. Weber DG, JohnenG, BrykO, Jöckel KH, Brüning T. Identification
of miRNA-103 in the cellular fraction of human peripheral
blood as a potential biomarker for malignant mesothelioma.
A pilot study. PLoS One. 2012;7: e30221.
112. Vachani A, Moon E, Albelda SM. Gene therapy for
mesothelioma. Curr Treat Options Oncol. 2011;12:173-80.
113. Haas AR, Sterman DH. Novel intrapleural therapies for
malignant diseases. Respiration. 2012;83:277-92.
114. Tada Y, Shimada H, Hiroshima K, Tagawa M. A potential
therapeutic strategy for malignant mesothelioma with gene
medicine. Biomed Res Int. 2013;2013:572609.
115. Melaiu O, Stebbing J, Lombardo Y, et al. MSLN gene silencing
has an anti-malignant effect on cell lines overexpressing
mesothelin deriving from malignant pleural mesothelioma.
PLoS One. 2014;9:e85935.
116. Alberti C. From molecular imaging in preclinical/clinical
oncology to theranostic applications in targeted tumor
therapy. Eur Rev Med Pharmacol Sci. 2012;16:1925-33.
117. Zhang H, Tian M, Li E, Fujibayashi Y, Shen LH, Yang DJ.
Molecular imaging-guided theranostics and personalized
medicine. J Biomed Biotechnol. 2012;2012:747416.
118. Bidlingmaier S, He J, Wang Y, et al. Identification of MCAM/
CD146 as the target antigen of a human monoclonal
antibody that recognizes both epithelioid and sarcomatoid
types of mesothelioma. Cancer Res. 2009;69:1570-7.
119. Hama Y, Urano Y, Koyama Y, et al. A target cell-specific
activatable fluorescence probe for in vivo molecular imaging
of cancer based on a self-quenched Avidin-Rhodamine
conjugate. Cancer Res. 2007;67:2791–9.
120. Ntziachristos V, Bremer C, Weissleder R. Fluorescence
imaging with near-infrared light: new technological
advances that enable in vivo molecular imaging. Eur Radiol
2003;13:195-208.
121. Morawski AM, Winter PM, Crowder KC, et al. Targeted
nanoparticles for quantitative imaging of sparse molecular
epitopes with MRI. Magn Reson Med. 2004;51:480-6.
122. Nayak TK, Bernardo M, Milenic DE, Choyke PL, Brechbiel MW.
Orthotopic pleural mesothelioma in mice: SPECT/CT and
MR imaging with HER1- and HER2-targeted radiolabeled
antibodies. Radiology. 2013 Apr;267(1):173-82.